Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham

This article was originally published in The Tan Sheet

Executive Summary

Sells A-200 lice treatment product line to Hogil Pharmaceutical, a privately held consumer and pet health care products firm based in Armonk, N.Y. SmithKline did not disclose terms of the deal, which is effective Dec. 31. SmithKline explained in a Dec. 30 press release that its decision to divest A-200, which is marketed in the U.S. and Puerto Rico, is part of the company's strategy to concentrate on its "core OTC brands." Hogil will receive "transitional services" from SmithKline for "up to one year," the release states
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel